Skip to main content
. Author manuscript; available in PMC: 2019 Dec 13.
Published in final edited form as: Liver Transpl. 2019 May 30;25(8):1155–1164. doi: 10.1002/lt.25438

FIG. 4.

FIG. 4.

Median (whiskers, IQR) absolute change in circulating (A) VEGFR-1 (pg/mL), (B) VEGFR-2 (pg/mL), (C) VEGFR-3 (pg/mL), and (D) TIE2-expressing M2 monocytes (% of CD14+ cells) from baseline to 8 and 12 weeks in patients receiving sorafenib (red) or placebo (blue). P values are for comparison with baseline.